Pfizer 10-Qquarter ended 2026-03-29

Executive Summary

Pfizer’s Q1 2026 revenue grew 5% Y/Y, but foreign exchange supplied most of the increase; excluding its declining coronavirus products, revenue grew 7% operationally. Oncology and specialty products gained ground, while higher production and research costs and a return to a normal tax provision reduced earnings. Management is using cost savings to fund its pipeline and manage approaching patent losses, with debt reduction taking priority over buybacks. For investors, the question is whether newer products and pipeline launches can replace revenue lost to exclusivity and pricing pressure without further eroding margins.

Key Financial Highlights

• Earnings quality: Operating cash flow was close to GAAP net income; ordinary-course receipt and payment timing and noncash adjustments affected conversion. Free cash flow subtracts $436M of capital expenditures.
• Cost pressure: Cost of sales rose 25% to $3.55B, reflecting, in part, a favorable royalty estimate revision that did not recur and $285M of unfavorable foreign-exchange effects. R&D rose 13% to $2.49B, including additional oncology and obesity spending.
• Taxes and valuation: The effective tax rate was 14.6% vs a 6.8% benefit a year earlier. A $295M increase in the fair value of contingent consideration, primarily related to Metsera, also weighed on results.
• Capital allocation: No shares were repurchased; actual shares outstanding rose from ≈5.69B at January 1 to ≈5.70B at quarter-end. Stock-based compensation rose to $272M from $170M. Interest expense was $668M, and long-term debt principal was $60.3B, alongside $3.89B of short-term borrowings including current maturities.

Business Developments

The revenue mix is shifting toward oncology and specialty care. Padcev, Nurtec ODT/Vydura and Lorbrena gained on treatment uptake and launches; Eliquis also grew despite international generic and price pressure. By contrast, Comirnaty and Paxlovid revenue fell to $232M and $186M, respectively. This makes growth outside coronavirus products more important to Pfizer’s trajectory.

Management plans to reinvest savings in its pipeline: its cost-base program delivered $5.1B of net savings through 2025 and targets another $600M by end-2026. Manufacturing optimization targets $1.5B of net savings by end-2027. The programs have execution costs: the enterprise-wide realignment is expected to cost $5.3B through 2027, with $4.3B incurred by quarter-end.

Pfizer is expanding its obesity and oncology options through the Metsera acquisition, which carried $8.0B of provisional acquired in-process R&D, and exclusive Mainland China commercialization rights to Sciwind’s obesity drug ecnoglutide. Subsequent to quarter-end, it received $1.88B for its ViiV stake, which had a zero carrying value. In May, the Food and Drug Administration approved breast-cancer treatment Veppanu; Pfizer and Arvinas were seeking a third-party commercialization partner.

Risk Assessment

• Exclusivity and pricing: Pfizer expects a $1.5B revenue headwind in 2026 from patent and regulatory exclusivity expiries, with losses accelerating through 2030; Medicare-negotiated pricing for Eliquis began in January.
• Margin and savings execution: Production and research spending outpaced revenue growth this quarter; planned savings and Metsera synergies must materialize to protect earnings as older products face competition.
• Debt and dividends: Long-term debt principal of $60.3B and $668M of quarterly interest expense constrain flexibility, while this quarter’s dividends exceeded free cash flow.
• Acquired-asset valuation: Goodwill and identifiable intangibles total $124B; clinical setbacks or weaker product forecasts could trigger impairment, while milestone assumptions can move the $2.04B contingent-consideration liability.
• Litigation and product competition: Patent challenges could accelerate generic entry, and unresolved product-liability and other cases may produce costs beyond accrued amounts that Pfizer cannot reasonably estimate.
• Trade and supply: Newly announced U.S. pharmaceutical tariffs could reach 100% on covered imports, depending on implementation and any Pfizer agreement; exposure could affect costs or supply decisions.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

Pfizer’s near-term thesis depends on newer medicines and launches growing quickly enough to absorb exclusivity losses while cost programs restore margins. Deleveraging remains a stated priority ahead of repurchases.

• Monitor operational revenue growth excluding Comirnaty and Paxlovid, alongside Padcev, Nurtec and Lorbrena sales: sustained growth would support the replacement-revenue thesis.
• Monitor gross margin and R&D spending against realized savings: improvement would show that restructuring is translating into earnings rather than merely funding higher costs.
• Monitor operating cash flow, dividends and debt: cash flow covering dividends with room for debt reduction would strengthen financial flexibility.